Alcoholic liver disease (ALD) is a progressive liver disease that can cause a series of complications, including cirrhosis, liver failure and hepatocellular carcinoma. Granulocytic myeloid-derived suppressor cell (gMDSC) populations have been observed to expand in various liver diseases and to inhibit innate and adaptive immunity in patients with liver disease. However, the characteristics of gMDSCs in patients with ALD have not been studied. We studied 24 healthy controls (HCs) and 107 patients with ALD and found an accumulation of gMDSCs in the peripheral blood of patients with alcoholic liver cirrhosis (ALC). Furthermore, ALC patients with a poor prognosis displayed a significant increase in peripheral gMDSCs and showed an increased capacity for arginase I production compared to HCs. In contrast, plasma arginase I levels in ALC patients were negatively correlated with total bilirubin and international normalized ratio, two key parameters of liver damage. Importantly, gMDSCs accumulated in the livers of ALC patients, and the frequency of liver gMDSCs significantly correlated with that of peripheral gMDSCs. In addition, gMDSC enrichment in vitro significantly inhibited the function of natural killer (NK) cells, perhaps preventing the NK-induced apoptosis of hepatic stellate cells. In summary, increased peripheral and intrahepatic gMDSC populations are present in patients with ALC and may contribute to enhancing the severity of liver cirrhosis.
innate and adaptive immunity through the production of arginase, reactive oxygen species (ROS) and interleukin-10 (IL-10). [7] [8] [9] MDSC accumulation leads to the sequestration of most of the available cysteine, which is essential for certain processes. The absence of cysteine prevents the production of proteins related to T cell activation. 10 In (gMDSCs). 11 Accumulating evidence indicates that gMDSCs produce high levels of arginase I, IL-10 and transforming growth factor-β (TGF-β) 7, [12] [13] [14] and play a vital role in regulating the immune environment. A relatively recent study showed that an increased gMDSC population inhibits T cell responses via an arginase-dependent pathway, thus sustaining HBV replication without overt liver injury. 11 However, whether gMDSCs can regulate the function of immunocytes in ALD patients remains unknown.
In the present study, we characterized gMDSCs in two groups of patients to determine the correlation between gMDSCs and the severity of ALD and found that the gMDSC population was increased in ALD patients and closely associated with disease progression.
| MATERIALS AND METHODS

| Patients
Blood samples were obtained from 105 individuals with ALD, including 16 AH patients and 89 ALC patients. All ALD patients were diagnosed according to existing criteria, 15, 16 and individuals with concurrent HBV, HCV, autoimmune liver disease or severe systemic disease were excluded. ALC patients were further subdivided based on the ChildPugh score, which is used to evaluate the prognosis of patients with ALC: A (5-6 points), B (7-9 points) and C (10-15 points). 17 Twenty-four sex-matched healthy individuals were enrolled as controls. 
| Flow cytometric analysis
All antibodies were purchased from Biolegend (San Diego, CA, USA), except for anti-CD14-APCH7, anti-CD3-PerCPCy5.5, antiCD107a-FITC and anti-IFN-γ-PECy7, which were purchased from BD Biosciences (Franklin Lakes, NJ, USA were stained with a Wright-Giemsa kit (Solarbio, Beijing, China)
following the manufacturer's instructions.
| Cell isolation
Peripheral blood mononuclear cells were isolated from freshly heparinized blood using protocols described previously by our team. 18 gMDSCs were isolated by CD14-negative selection, followed by CD15-positive selection, using anti-CD14 and anti-CD15 antibody-coated magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Natural killer (NK) cells were isolated by negative selection using an NK isolation kit. All assays were performed according to the manufacturers'
instructions. The purity of the separated cells ranged from 95% to 98%.
| Cell culture
Purified NK cells cocultured with or without enriched gMDSCs (at a ratio of 1:1) were stimulated with PMA (50 ng/mL) and ionomycin
(1 μg/mL) (Sigma Aldrich, St. Louis, MO, USA) at 37°C for 6 hours.
Anti-CD107a antibody was added at the beginning of the stimulation period, and monensin was added 1 hour later. To further investigate the potential suppressive mechanisms by gMDSCs, 500 μmol/L Nω-Hydroxy-nor-L-arginine, diacetate salt (nor-NOHA; Calbiochem, Darmstadt, Germany) was added in the culture system.
| Immunohistochemistry and confocal microscopy
Paraffin-embedded and formalin-fixed liver tissue sections (5 μm thick)
were incubated with anti-CD15 antibody (Novus Biological, Littleton, CO, USA) and/or anti-CD66b antibody (BD Bioscience) overnight at 4°C after endogenous peroxidase activity was blocked with 0.3% H 2 O 2 . Then, the colorimetric substrate 3-amino-9-ethyl-carbazole (red colour) was added, followed by counterstaining with haematoxylin for single staining according to previously described protocols. 19 Images were captured at high magnification (400×) by an Olympus CX31 microscope and Olympus FV1000 confocal microscope.
20,21
| HPLC-MS/MS for amino acid quantification
Plasma L-arginine levels were determined using an API 3200 QTRAP HPLC-LC MS/MS as described elsewhere. 
| Enzyme-linked immunosorbent assay
Commercial kits were used for detecting arginase (Hycult, Uden, The Netherlands) according to the manufacturer's protocols. The detection limit of arginase I was 13 ng/mL.
| Statistical analysis
All data were analysed using SPSS 20.0 software. The quantitative data are presented as the mean ± SD. Figure 1A ). Wright-Giemsa staining confirmed the granulocytic nature of the gMDSCs population analysed ( Figure 1B ).
As shown in Figure 1C , the frequency of gMDSCs was significantly higher in ALD patients than in HCs. The frequency of gMDSCs in ALD patients was highly variable; in some subjects, the expanded and ALC groups (P < 0.001) have a higher frequency of gMDSCs compared with HCs, whereas there was no significant difference between AH and ALC groups (P = 0.662) ( Figure 1C ).
Child-Pugh scores are used to determine the prognosis of liver cirrhosis, and higher scores predict poor prognosis. For ALC patients, Child-Pugh B and C patients have a greater population of gMDSCs than do Child-Pugh A patients ( Figure 1D ). However, there was no significant difference between Child-Pugh B and C patients. These data indicate that gMDSCs have a role in ALD and suggest that the increased frequency of gMDSCs in ALD patients is closely associated with disease progression.
| Arginase + gMDSCs were increased in ALD patients
As shown in Figure 2A , gMDSCs showed stronger staining than other cell types for arginase I (Figure 2A ). In the ALD and HC groups, gMDSCs showed almost 100% staining for arginase I compared to the isotype control ( Figure 2B ). As shown in Figure 2C , the proportion of arginase + gMDSCs was elevated in both AH and ALC patients compared to HCs. Then, we analysed the difference in the arginase + gMDSC frequency in ALC patients based on Child-Pugh score. We noted a significant increase in the arginase + gMDSC frequency in Child-Pugh B and C patients compared with Child-Pugh A patients ( Figure 2D ).
| gMDSCs were enriched in the livers of ALD patients
To determine whether gMDSCs accumulated in the liver of ALD patients, we first stained liver tissues for CD15 and CD66b, two markers of gMDSCs. As shown in Figure 3A , a few CD15-or CD66b-positive cells were found in liver tissues from HCs, while the number of such cells was considerably higher in liver tissues from ALC patients than from HCs or those with AH ( Figure 3B ). Importantly, more CD15-or CD66b-positive cells were observed in the liver sinusoids in ALC patients. These data were further validated by double epitope staining and confocal microscopy ( Figure 3C ). In addition, we found that ALC patients with a higher number of circulating gMDSCs had more intrahepatic gMDSCs ( Figure 3D ,E). In addition, both circulating and intrahepatic gMDSCs highly expressed arginase I compared with the isotype control ( Figure 3F ). These data suggest considerable accumulation of gMDSCs in the livers of ALC patients, and this infiltration of gMDSCs is closely associated with their peripheral counterparts.
| Arginase I concentration was increased in ALD patients
We further analysed plasma arginase I levels and found that corresponding with the frequency of arginase + gMDSCs, the plasma arginase level was markedly higher in ALD patients than in HCs.
Interestingly, AH patients had a higher arginase I levels than did ALC patients ( Figure 4A ). In contrast with the results for arginase Figure 4C ). In addition,
we found that the arginase I concentration was negatively with MELD score in ALC group ( Figure 4C) . Importantly, as shown in Figure 4D , the plasma L-arginine concentration was significantly lower in ALD patients than in HCs.
| gMDSCs from ALD patients showed enhanced suppressive function
Activated NK cells play an important role in attenuating liver cirrhosis by killing hepatic stellate cells (HSCs). 22 We cultured NK We further compared the inhibitory activity of gMDSCs from ALD Figure 5C ). These results strongly suggest that suppressive effect of gMDSCs is primarily mediated through the production of arginase in ALD patients.
| DISCUSSION
Myeloid-derived suppressor cells were first described in the early 1900s, but it was not until the late 1970s that the phenotypes, function and nomenclature of MDSCs began to be studied. 23 In recent years, researchers have become increasingly more interested in the immunoregulatory role of MDSCs. However, until now, the characteristics of MDSCs in ALD patients had not been reported. In our study, we found that the gMDSC population was increased in ALD patients and was closely associated with disease severity. We also provide evidence for the enhanced suppressive function of gMDSCs in ALD.
Myeloid-derived suppressor cells can be further divided into the mMDSC and gMDSC subsets based on phenotype and origin. In the hepatology field, mMDSCs play a role in chronic inflammatory liver disease. The frequencies of peripheral and intrahepatic mMDSCs correlate with liver inflammatory injury and viral load in chronic viral hepatitis 24, 25 and are associated with disease severity and prognosis in primary biliary cholangitis. 26 mMDSCs accumulate in hepatocellular carcinoma (HCC), and a higher mMDSC frequency (more than 30.5% of CD14 + cells) indicates a shorter survival of HCC patients treated with hepatic arterial infusion chemotherapy. 13 There are significantly more mMDSCs in the liver in patients with non-alcoholic fatty liver disease than in HCs. 27 In recent years, the characteristics of gMDSCs have become an increasingly popular research topic. Expanded gMDSCs impede antiviral therapy for chronic hepatitis B patients in the immunotolerant phase. 
